Vitals Knowledge Vault

Orforglipron

9 min read

Orforglipron

TL;DR

Orforglipron (Foundayo; LY3502970) is an oral, non-peptide small-molecule GLP-1 receptor agonist approved by the FDA on 2026-04-01 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. It is not FDA-approved for type 2 diabetes in the Batch 175 source set, even though ACHIEVE-3 shows meaningful A1C lowering.

The clean label-aligned efficacy frame is moderate GLP-1 weight loss with high convenience: about -11.1% body weight at 72 weeks in adults without diabetes and -9.6% in adults with T2D. ACHIEVE-3 showed better A1C and weight outcomes than oral semaglutide 14 mg, but orforglipron is still expected to trail injectable semaglutide, tirzepatide, and Retatrutide on absolute weight-loss ceiling.

For Vitals, the value is not “best GLP-1.” The value is a no-injection, no-SNAC, no-fasting GLP-1 option that still needs serious coaching around GI tolerance, protein intake, resistance training, wearable confounds, contraindications, and discontinuation/regain risk.

Why it matters for Vitals

  • Metabolic coaching: Orforglipron can materially improve weight and glycemia, but Vitals should coach it as a GLP-1 mono-agonist with an efficacy/convenience trade-off rather than a maximal-weight-loss protocol.
  • HRV and recovery interpretation: no orforglipron-specific HRV studies exist. During dose escalation, nausea, dehydration, under-eating, and sleep disruption may suppress HRV or raise resting HR without reflecting true fitness loss.
  • Wearable implications: expected signals are indirect: weight trend, resting HR, sleep fragmentation from GI symptoms, glucose/CGM improvement in T2D, and possible readiness noise during titration. There is no validated wearable signature for orforglipron response.
  • Body composition: no dedicated lean-mass data are available. Use GLP-1 Body Composition, GLP-1 Muscle Preservation, and Incretin Sarcopenia GLP-1 Prevention Protocol assumptions until orforglipron-specific DXA data exist.
  • Discontinuation risk: GI symptoms are the main early adherence threat. If therapy stops, rebound appetite, weight regain, and glycemic drift should be treated as likely GLP-1-class risks, but the exact orforglipron discontinuation trajectory is not established.

Key facts

TopicCurrent best summary
ClassOral non-peptide small-molecule GLP-1 receptor agonist
Brand / codeFoundayo; LY3502970
SponsorEli Lilly (discovered by Chugai); approved NDA 220934
FDA statusApproved 2026-04-01, NDA 220934, for chronic weight management in obesity/overweight + comorbidity
T2D statusStrong T2D efficacy data, but not FDA-approved for T2D in the Batch 175 source set
Dosing advantageOnce-daily tablet; can be taken with or without food; no injection, cold chain, SNAC carrier, or fasting requirement
Label-aligned weight loss-11.1% at 72 weeks in non-diabetic obesity trial; -9.6% at 72 weeks in obesity + T2D trial
ACHIEVE-3 vs oral semaglutideA1C -1.91% vs -1.47% using treatment-regimen estimand; weight -9.2% vs -5.3%
Main adverse eventsNausea, vomiting, diarrhea, constipation; concentrated in early titration weeks
Key label warningsThyroid C-cell tumor boxed warning; pancreatitis, gallbladder disease, delayed gastric emptying/aspiration, pregnancy, DILI monitoring
Drug interaction notesCYP3A4 substrate; simvastatin exposure increased about 2-fold; delayed gastric emptying can affect oral drug absorption
Available tablet strengths0.8 / 2.5 / 5.5 / 9 / 14.5 / 17.2 mg (film-coated, color-coded)
Price~149/month cash-pay starter; ~1,050/month list
Biggest evidence gapsNo completed CV outcomes result (ATTAIN-Outcomes est. Aug 2031), no >72-week controlled safety, no lean-mass data, no real-world adherence comparison

Critical corrections from queue rationale and prior batches

Queue rationale was wrong: A frontier-scout entry claimed FDA approval for T2D in December 2025. This is not supported by primary FDA databases. The only confirmed FDA approval is April 1, 2026 for obesity (NDA 220934). T2D remains investigational. Lilly’s stated plan is to submit for T2D indication in 2026.

Sponsor correction: Do not list Zoetis as sponsor. Orforglipron was discovered by Chugai and is marketed by Eli Lilly.

Do not use “12.4%” as the primary label-aligned weight-loss claim. The correct FDA-label-aligned figure is -11.1% for Foundayo 17.2 mg at 72 weeks in Trial 1 (NCT05869903). The 12.4% figure belongs to ATTAIN-1 at a 36 mg investigational/development dose and should only be used with explicit context that it is the highest-dose arm, not the approved label dose.

Mechanism summary

Orforglipron activates GLP-1R through a transmembrane allosteric pocket rather than the extracellular peptide-binding domain used by endogenous GLP-1 and peptide GLP-1 drugs. Reported mechanistic features include:

  • Ki roughly 1-3.2 nM and cAMP EC50 roughly 0.34-1.2 nM in source assays.
  • Selectivity reported as >10,000× over GLP-2R, GIPR, and GCGR.
  • G-protein/Gs-biased signaling with minimal β-arrestin recruitment; clinical relevance remains uncertain.
  • GLP-1-class downstream effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite suppression, and secondary improvements in cardiometabolic markers.

The practical interpretation is conservative: orforglipron is a differentiated delivery chemistry and receptor-binding implementation, but clinically it remains a GLP-1 mono-agonist. That helps explain why it is useful and convenient but not expected to match dual/triple incretin agents on weight-loss magnitude.

Evidence summary

Stronger source-backed findings

  • Regulatory: FDA approval letter and label support approval on 2026-04-01 for chronic weight management in obesity/overweight adults with comorbidity; no REMS required.
  • Weight loss, Trial 1 / NCT05869903: Foundayo 17.2 mg once daily for 72 weeks produced -11.1% mean weight change; responder rates included 71.5% ≥5%, 54.5% ≥10%, 35.9% ≥15%, and 18.4% ≥20% weight loss.
  • Weight loss, Trial 2 / NCT05872620: in obesity + T2D, Foundayo 17.2 mg produced −9.6% mean weight change at 72 weeks and A1C reduction around −1.7%.
  • ATTAIN-MAINTAIN: Phase 3 trial in patients with prior GLP-1 RA use — provides switching/sustainability data.
  • ACHIEVE-3: orforglipron outperformed oral semaglutide 14 mg on A1C using the treatment-regimen estimand (-1.91% vs -1.47%) and on weight (-9.2% vs -5.3%) over 52 weeks.
  • Convenience: oral bioavailability 79.1% without SNAC carrier; no fasting or water restrictions; room-temperature storage; six color-coded tablet strengths (0.8 / 2.5 / 5.5 / 9 / 14.5 / 17.2 mg) — real differentiators from oral semaglutide.
  • Tolerability: GI adverse events are common, especially early in titration, and are the highest practical adherence/coaching issue.

Comparative interpretation

  • Versus oral semaglutide: ACHIEVE-3 supports better glycemic and weight outcomes than oral semaglutide 14 mg, but with more GI tolerability burden in the broader source corpus.
  • Versus injectable semaglutide / tirzepatide / retatrutide: no head-to-head trials against injectables were found. Cross-trial comparisons suggest lower absolute weight loss than injectable semaglutide and substantially lower than tirzepatide or retatrutide.
  • Versus broader Vitals GLP-1 strategy: orforglipron is best framed as an access/adherence option for users who refuse injections or cannot comply with oral semaglutide fasting restrictions.

Projection / not established

  • Orforglipron-specific HRV, sleep architecture, lean-mass, and CGM pattern data are not published in the Batch 175 source set.
  • Cardiovascular protection is not established; ACHIEVE-4 CVOT/DILI results were still pending in the source set.
  • Real-world adherence advantage is plausible but unproven.
  • Automated Vitals dose adjustment from wearable signals is not ready for protocol use.

Risks and uncertainty

  • GI tolerance: nausea, vomiting, diarrhea, and constipation can impair hydration, nutrition, sleep, exercise adherence, and readiness scores. Coaching should focus on early titration weeks. GI discontinuation rates run 5–10% across the Phase III program.
  • Thyroid boxed warning: contraindicated or high-caution context for personal/family medullary thyroid carcinoma or MEN2, consistent with GLP-1 RA class labeling.
  • Pancreatitis and gallbladder disease: severe abdominal pain, persistent vomiting, or gallbladder symptoms require escalation, not routine coaching.
  • Delayed gastric emptying: relevant for gastroparesis risk, peri-procedural aspiration risk, and absorption of other oral medications. Oral contraceptives require non-hormonal backup for 30 days after orforglipron discontinuation (CYP3A4 interaction affecting contraceptive metabolism).
  • DILI monitoring: FDA required post-approval liver safety monitoring (April 14, 2026 — 13 days after approval) — DILI Hy’s Law monitoring appears in FDA postmarketing requirements; do not treat hepatic safety as settled.
  • Pregnancy/lactation/pediatrics: safety remains incomplete; ADVANCE-ATTAIN-ADOLESCENTS (NCT06672939, ages 12–17) is actively recruiting. Multiple postmarketing requirements and registries are pending.
  • Body composition: no orforglipron-specific lean-mass preservation evidence. Protein and resistance training are practical safeguards, not proven orforglipron-specific antidotes.
  • Cardiovascular outcomes: no completed CVOT result; ATTAIN-Outcomes (NCT07241390, n=7,140, ASCVD/CKD population) estimates completion August 2031. Do not claim MACE reduction or cardioprotection.
  • Discontinuation/regain: long-term maintenance after stopping is not established. GLP-1-class experience makes regain a realistic planning risk.
  • Ongoing investigational programs: beyond obesity, orforglipron is in active trials for OSA, hypertension, peripheral artery disease (PAD), and stress urinary incontinence — none are approved indications.

Likely wearable / Vitals relevance

  • Weight: track trend and rate of loss; rapid scale changes should trigger protein, hydration, and resistance-training checks rather than celebration by default.
  • Glucose / CGM: T2D users may show lower average glucose and better time-in-range, but non-diabetic CGM optimization claims should remain cautious. See CGM for Non-Diabetics.
  • HRV: likely confounded during GI symptoms, under-fueling, dehydration, poor sleep, and titration. Do not infer dose response from HRV alone.
  • Resting heart rate: GLP-1 agents can raise heart rate modestly; persistent or symptomatic elevation needs clinician review.
  • Sleep: GI symptoms may fragment sleep early; later sleep improvement may come indirectly from weight loss and metabolic improvement, not a direct sleep-enhancing mechanism.
  • Readiness: poor readiness scores during titration can reflect medication side effects rather than overtraining.

Best stack context

  • Best fit: users who need GLP-1 metabolic help but strongly prefer oral therapy or cannot manage injections/cold-chain logistics.
  • Required baseline stack: adequate protein, resistance training, hydration, sleep hygiene, and body-composition monitoring.
  • Medication context: metformin or SGLT2 inhibitor combinations may be plausible in T2D care, but medication changes and hypoglycemia risk require clinician review.
  • Poor fit: severe GI sensitivity, gastroparesis, pancreatitis history, gallbladder instability, MTC/MEN2 history, pregnancy/lactation, or complex polypharmacy without clinician oversight.
  • Do not stack with another GLP-1 RA: overlapping pharmacology; no routine evidence-based reason to combine.

What stays inside this hub

  • Orforglipron-specific dosing/formulation distinctions.
  • The 12.4% vs 11.1% claim correction.
  • Allosteric binding and biased-signaling details until multiple notes need a reusable mechanism node.
  • GI coaching and discontinuation-risk interpretation.
  • Wearable projections, because no orforglipron-specific detection model exists yet.

No new mechanism, biometric, or detection-model note was created for Batch 175. Existing reusable notes already cover the useful graph edges.

Graph View

Backlinks